RecruitingSolid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07517198 · last updated 2026-06-10